Justices Won't Take Up Novartis-HEC Feud Over MS Drug
The U.S. Supreme Court on Monday rebuffed Novartis Pharmaceuticals' call for it to review a Federal Circuit ruling that invalidated the drugmaker's patent on blockbuster multiple sclerosis treatment Gilenya....To view the full article, register now.
Already a subscriber? Click here to view full article